Search This Blog

Wednesday, November 30, 2022

bluebird bio Sells Priority Review Voucher for $102 M

 bluebird bio, Inc. (NASDAQ: BLUE) ("bluebird bio" or the "Company") today announced that it has entered into a definitive agreement to sell a Rare Pediatric Disease Priority Review Voucher (PRV) for $102 million.

bluebird was granted two PRVs upon the US Food and Drug Administration (FDA) approvals of ZYNTEGLO® (betibeglogene autotemcel) for the treatment of beta-thalassemia in adult and pediatric patients requiring regular red blood cell transfusions and SKYSONA® (elivaldogene autotemcel) for the treatment of early, active cerebral adrenoleukodystrophy, on August 17, 2022 and September 16, 2022 respectively.

https://finance.yahoo.com/news/bluebird-bio-sells-priority-review-120000491.html

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.